沃森生物(300142.SZ):收到一項發明專利證書 為一種同時製備兩種單克隆抗體的方法
格隆匯 3 月 1日丨沃森生物(300142.SZ)公佈,公司於近日收到一項由中華人民共和國國家知識產權局頒發的發明專利證書,發明名稱為一種同時製備兩種單克隆抗體的方法。
該發明公開了一種同時製備兩種單克隆抗體的方法,所述方法以33F型肺炎多糖與乙肝表面蛋白的偶聯物作為抗原免疫小鼠,選取免疫後抗體水平較高的小鼠脾細胞與SP2/0骨髓瘤細胞融合,再通過33F肺炎多糖、乙肝表面蛋白以及33F型肺炎多糖與乙肝表面蛋白偶聯物作為抗原進行特異性篩選,獲得雜交瘤細胞,同時製備出特異性識別33F肺炎多糖和乙肝表面蛋白的單克隆抗體。本發明這種以乙肝表面蛋白為載體的肺炎偶聯物免疫後同時製備分別針對多糖與蛋白的單克隆細胞株細胞及特異性單抗的方法,節省了工作量,提高篩選效率,同時本發明提供的兩種單抗具有特異性高,敏感度高及傳代穩定性好的優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.